SG10201806064XA - Anti-tumor compositions and methods - Google Patents

Anti-tumor compositions and methods

Info

Publication number
SG10201806064XA
SG10201806064XA SG10201806064XA SG10201806064XA SG10201806064XA SG 10201806064X A SG10201806064X A SG 10201806064XA SG 10201806064X A SG10201806064X A SG 10201806064XA SG 10201806064X A SG10201806064X A SG 10201806064XA SG 10201806064X A SG10201806064X A SG 10201806064XA
Authority
SG
Singapore
Prior art keywords
tumors
methods
tumor
nanoparticle
tumor compositions
Prior art date
Application number
SG10201806064XA
Other languages
English (en)
Inventor
Thomas Primiano
Bey-Dih Chang
Original Assignee
Peptimed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptimed Inc filed Critical Peptimed Inc
Publication of SG10201806064XA publication Critical patent/SG10201806064XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG10201806064XA 2014-08-27 2015-06-15 Anti-tumor compositions and methods SG10201806064XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462070495P 2014-08-27 2014-08-27

Publications (1)

Publication Number Publication Date
SG10201806064XA true SG10201806064XA (en) 2018-08-30

Family

ID=53491686

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201701402QA SG11201701402QA (en) 2014-08-27 2015-06-15 Anti-tumor compositions and methods
SG10201806064XA SG10201806064XA (en) 2014-08-27 2015-06-15 Anti-tumor compositions and methods

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201701402QA SG11201701402QA (en) 2014-08-27 2015-06-15 Anti-tumor compositions and methods

Country Status (10)

Country Link
US (1) US10111898B2 (fr)
EP (1) EP3186378A1 (fr)
JP (1) JP2017530948A (fr)
KR (1) KR20170041277A (fr)
CN (1) CN106714811A (fr)
AU (1) AU2015307186A1 (fr)
BR (1) BR112017003986A2 (fr)
CA (1) CA2959492A1 (fr)
SG (2) SG11201701402QA (fr)
WO (1) WO2016032595A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102434541B1 (ko) 2014-01-17 2022-08-19 세다르스-신나이 메디칼 센터 수용체 표적화 작제물 및 이의 용도
AU2015240460A1 (en) 2014-04-04 2016-09-15 Cedars-Sinai Medical Center Targeting trastuzumab-resistant HER2+breast cancer with a HER3-targeting nanoparticle
CA2983832A1 (fr) * 2015-04-30 2016-11-03 Histogen, Inc. Composition de matrice extracellulaire pour le traitement du cancer ou des maladies immunologiques
US11110168B2 (en) 2016-03-15 2021-09-07 North Carolina State University Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent
BR112018074304A2 (pt) * 2016-05-27 2019-10-01 Cedars Sinai Medical Center composições de nanopartículas, kit e método para tratar um indivíduo com câncer resistente a fármacos

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (fr) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Composition pharmaceutique contenant de l'urokinase
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
EP0642589A4 (fr) 1992-05-11 1997-05-21 Ribozyme Pharm Inc Procede et reactif d'inhibition de la replication virale.
AU4769893A (en) 1992-07-17 1994-02-14 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
WO1999004819A1 (fr) 1997-07-24 1999-02-04 Inex Pharmaceuticals Corporation Compositions de liposomes pour la distribution des catalyseurs de l'acide nucleique
WO1999031262A2 (fr) 1997-12-16 1999-06-24 Valentis, Inc. Injection sans aiguille de molecules d'acide nucleique formules
EP1159441B8 (fr) 1999-03-10 2008-10-29 Marie Curie Cancer Care Administration de substances a des cellules
AU2007269052B2 (en) * 2006-07-06 2014-10-23 Array Biopharma Inc. Cyclopenta [D] pyrimidines as AKT protein kinase inhibitors
MX2009002065A (es) * 2006-08-23 2009-06-30 Korea Res Inst Of Bioscience Una composicion farmaceutica para tratar cancer pulmonar, un metodo para inhibir el crecimiento o invasion de cancer pulmonar y un metodo para tratar cancer pulmonar.
US20110257244A1 (en) * 2008-01-18 2011-10-20 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
AU2011323508B2 (en) * 2010-11-01 2017-04-27 Peptimed, Inc. Compositions of a peptide targeting system for treating cancer
CN104271740A (zh) * 2011-04-20 2015-01-07 L·J·史密斯 利用在细胞中自组装和产生RNAi活性的成分来调节基因表达的方法和组合物
CN103566377A (zh) * 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
KR20170041277A (ko) 2017-04-14
BR112017003986A2 (pt) 2018-02-27
US10111898B2 (en) 2018-10-30
WO2016032595A1 (fr) 2016-03-03
AU2015307186A1 (en) 2017-04-13
CN106714811A (zh) 2017-05-24
US20160058784A1 (en) 2016-03-03
CA2959492A1 (fr) 2016-03-03
SG11201701402QA (en) 2017-03-30
JP2017530948A (ja) 2017-10-19
EP3186378A1 (fr) 2017-07-05

Similar Documents

Publication Publication Date Title
MX2020012573A (es) Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b.
MX2019005617A (es) Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
PH12018501473A1 (en) Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
MX2021008498A (es) Celulas t modificadas en receptor de antigeno quimerico dirigo a cs1.
ECSP17064523A (es) Composiciones y métodos para activar la señalización dependiente del "estimulador del gen de interferon"
WO2014191359A9 (fr) Aptamères et utilisation d'aptamères dans le diagnostic et le traitement du cancer
MX2017007321A (es) Terapias de combinacion.
MX2022005955A (es) Metodos y composiciones para terapia celular adoptiva.
SA517381666B1 (ar) B مستقبلات مولد ضد خيمري تستهدف مولد ضد نضج الخلايا
MX2018005468A (es) Terapia dirigida contra el cáncer.
SG10201806064XA (en) Anti-tumor compositions and methods
TW201613648A (en) Compounds and compositions for immunotherapy
SG10201900727QA (en) Personalized immunotherapy against several neuronal and brain tumors
MY174248A (en) Targeted/immunomodulatory fusion proteins and methods for making same
TW201613956A (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
MX2017002085A (es) Tratamientos con nanopartículas núcleo-corteza de proteína/oligonucleótido.
EP3698631A3 (fr) Procédés d'administration d'oligonucléotides dans des cellules immunes
WO2014167126A3 (fr) Plateforme pour l'administration ciblée à des cellules souches et des cellules tumorales et ses procédés
MX2018001755A (es) Vacuna contra viruela para tratamiento del cancer.
IN2015DN00263A (fr)
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
MX2017012867A (es) Composiciones terapeuticas y metodos de uso para tratar el cancer.
SI3460052T1 (sl) Izboljšane alogene dendritične celice za uporabo pri zdravljenju raka
MY195739A (en) Functionalised Benzopyran Compounds and use Thereof
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.